On October 10, at the site of the Single Distributor, a meeting was held with the representative office of the German pharmaceutical company “Boehringer Ingelheim Pharma Gesellschaft mbH” in the Republic of Kazakhstan, headed by the Director of the Branch, Typhoon Merich.
The organization's activities include the production of innovative medicines for the treatment of socially significant diseases: diabetes mellitus, chronic heart failure, respiratory diseases, ischemic stroke and myocardial infarction, as well as cancer.
During the meeting, the parties considered the possibilities of localizing production in Kazakhstan within the framework of contract manufacturing.
The head of state in his message instructed to increase the share of domestically produced medicines and medical products to 50% by 2025. In addition, he noted the need to attract investors, ensure the transfer of leading technologies and the latest developments, expand the volume and range of off-take contracts with domestic manufacturers.
Chairman of the Board of the Unified Distributor Erkhat Iskaliev, in turn, spoke about the unified distribution system, contract manufacturing mechanisms and work with a number of BigPharma companies on projects for the production of innovative drugs with the possibility of exporting to near and far abroad.
The German side was presented with the investment opportunities of the industry and the conditions of government benefits and preferences, the high potential of the Kazakh pharmaceutical market and the prospects for its development. It should be noted that the support measure in the pharmaceutical industry is provided by the Single Distributor in the form of concluding long-term contracts for 10 years, which allows localizing the production of original drugs in the country.
In order to simplify the entry of global players into the domestic market, the Single Distributor has carried out work to improve regulations, which today make it possible to localize the production of drugs from world brands in the country, as well as to increase the pace of development and launch of new production facilities in Kazakhstan.
Continuing the topic of investments, a guide for potential investors - Investment Guide Book, prepared jointly with Kazakh Invest for the convenience of potential investors, was also presented to the participants.
It is worth noting that today an agreement has been concluded between the Single Distributor and Boehringer Ingelheim Pharma GmbH for the supply of 16 types of medicines of the company, which have no analogues in the Republic of Kazakhstan. The total contract amount is over 14 billion tenge.
As a result of the meeting, an agreement was reached on the need for local elaboration of issues of transfer of production technologies at the sites of Kazakh pharmaceutical manufacturers and their deep localization on the territory of the republic.
In addition, the possibility of signing a bilateral Memorandum of Cooperation and Understanding between the Ministry of Health of the Republic of Kazakhstan and the company Boehringer Ingelheim Pharma GmbH is being considered in the near future.
In conclusion, the parties voiced the possibilities of increasing bilateral cooperation in the field of pharmaceutical production and outlined the prospects for mutually beneficial cooperation between Germany and Kazakhstan as a whole.
For reference:
Boehringer Ingelheim works on revolutionary treatments that change people's lives today and for future generations. As a leading research-driven biopharmaceutical company, Boehringer Ingelheim brings high value through innovation in areas of high unmet medical need.
Founded in 1885, the company is a family-owned business with a long-term, sustainable vision. More than 53 thousand employees serve more than 130 markets in two business units, Human Pharma and Animal Health.
.jpeg)
